Geron Corp. operates as a biopharmaceutical company which discovers and develops therapeutic products for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is a product candidate in clinical development.

Research Grants 38 show all


$620.3K
2000

$632.7K
2001

$796.1K
2002

$248.6K
2003

$1.1M
2004

Patents 1,107show all

  • 436
    C12N - Microorganisms or enzymes
  • 312
    A61K - Preparations for medical, dental, or toilet purposes
  • 146
    C12Y - Enzymes
  • 130
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 97
    A01K - Animal husbandry
  • 78
    C07K - Peptides
  • 59
    C07H - Sugars
  • 38
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 25
    C07D - Heterocyclic compounds
  • 21
    A01N - Preservation of bodies of humans or animals or plants or parts thereof

Clinical Trials 23show all

8Phase 18Phase 25Phase 2/Phase 32N/A

SEC Filings show all


253
8-K

71
10-Q

24
10-K

1
S-1

Contact Information

149 Commonwealth Drive
Menlo Park, CA 94025
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$96,700,00051-1002014-02-04Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2014-02-04$96,700,000Post Ipo Equity